SLE – Hematopoietic stem cell transplantation for systemic lupus erythematosus 英文参考文献.docVIP

Available online /content/5/5/207 Commentary SLE Hematopoietic stem cell transplantation for systemic lupus erythematosus Richard K Burt and Ann E Traynor Division of Immunotherapy, Northwestern University School of Medicine, Chicago, Illinois, USA Correspondence: Richard K Burt (e-mail: rburt@) Received: 5 Mar 2003 Accepted: 27 May 2003 Published: 26 Jun 2003 Arthritis Res Ther 2003, 5:207-209 (DOI 10.1186/ar786) ? 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362) Abstract Hematopoietic stem cell transplantation was first reported for patients with systemic lupus erythematosus in 1997. The procedure has since been performed worldwide including in Europe, in Brazil, and in China. A National Institutes of Health-funded phase III clinical trial of hematopoietic stem cell transplantation for refractory systemic lupus erythematosus is anticipated to begin in 2003. Encouraging responses are raising new hope about the role of adult hematopoietic stem cells in systemic lupus erythematosus. Keywords: hematopoietic stem cell transplantation, lupus Introduction The prognosis of systemic lupus erythematosus (SLE) 90 mg/kg equine antithymocyte globulin (ATG) (divided as 30 mg/kg over 3 days) was selected. markedly improved following the introduction of monthly intravenous pulse cyclophosphamide (500–1000 mg/m2). To collect hematopoietic stem cells, they need to be mobi- lized into the peripheral blood with either a hematopoietic colony stimulating factor such as granulocyte-colony stim- ulating factor or a chemotherapeutic drug such as cyclophosphamide, or both. Since granulocyte-colony stimulating factor is a proinflammatory cytokine that by Nevertheless, despite pulse cyclophosphamide and advances in supportive care such as new antihypertensive medications, patients with active SLE involving visceral organs have 2-year and 5-year morta